Skip to main content
. 2017 Jul 28;12(7):e0182166. doi: 10.1371/journal.pone.0182166

Fig 2. PKM2 expression decreases the survival of patients and PKM2 inhibition disrupts the glycolytic pathway in ovarian cancer cells.

Fig 2

(A) Kaplan–Meier analysis of the probability of progression-free survival (p = 0.01) (left) and overall survival (p = 0.057) (right) in patients with ovarian cancer, stratified according to PKM2 expression (n = 88). (B) Expression of PKM2 in different ovarian cancer cell lines. (C and D) Time-dependent inhibition of glucose consumption (**p<0.01,***p<0.001) and lactate production in CP70 and SKOV3 cells following shikonin treatment. PKM2, Pyruvate kinase M2.